{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T20:22:16Z","timestamp":1769545336750,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13300-025-01817-5","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:56:19Z","timestamp":1762505779000},"page":"55-72","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk\u2013Benefit Trade-offs of GLP-1RAs and SGLT-2is in Type 2 Diabetes Mellitus (T2D): Systematic Review, Meta-Analysis, and Net Benefit Modeling"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4141-5187","authenticated-orcid":false,"given":"Samit","family":"Ghosal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuradha","family":"Ghosal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"issue":"3","key":"1817_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2004","volume":"7","author":"MJ Hossain","year":"2024","unstructured":"Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: early detection should be focused. Health Sci Rep. 2024;7(3):e2004. https:\/\/doi.org\/10.1002\/hsr2.2004.","journal-title":"Health Sci Rep"},{"issue":"2_suppl","key":"1817_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2047487319878371","volume":"26","author":"E Dal Canto","year":"2019","unstructured":"Dal Canto E, Ceriello A, Ryd\u00e9n L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_suppl):25\u201332. https:\/\/doi.org\/10.1177\/2047487319878371.","journal-title":"Eur J Prev Cardiol"},{"key":"1817_CR3","doi-asserted-by":"publisher","first-page":"1513008","DOI":"10.3389\/fendo.2025.1513008","volume":"16","author":"X Ma","year":"2025","unstructured":"Ma X, Liu R, Xi X, Zhuo H, Gu Y. Global burden of chronic kidney disease due to diabetes mellitus, 1990\u20132021, and projections to 2050. Front Endocrinol (Lausanne). 2025;16:1513008. https:\/\/doi.org\/10.3389\/fendo.2025.1513008.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1817_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12933-021-01229-2","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, Maiorino MI, Bellastella G, Esposito K. The residual cardiorenal risk in type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):36. https:\/\/doi.org\/10.1186\/s12933-021-01229-2.","journal-title":"Cardiovasc Diabetol"},{"key":"1817_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024","volume":"75","author":"N Alfaris","year":"2024","unstructured":"Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. EClinicalMedicine. 2024;75:102782. https:\/\/doi.org\/10.1016\/j.eclinm.2024.","journal-title":"EClinicalMedicine"},{"key":"1817_CR6","doi-asserted-by":"publisher","unstructured":"McLean P, Bennett J, \u201cTrey\u201d Woods E, Chandrasekhar S, Newman N, Mohammad Y, et al. SGLT-2is across various patient populations in the era of precision medicine: the multidisciplinary team approach. NPJ Metab Health Dis. 2025;3:29. https:\/\/doi.org\/10.1038\/s44324-025-00068-z.","DOI":"10.1038\/s44324-025-00068-z"},{"issue":"1","key":"1817_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1817_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2217\/clp.13.8","volume":"8","author":"M Rizzo","year":"2013","unstructured":"Rizzo M, Nikolic D, Banach M, Giglio RV, Patti AM, Bartolo VD, et al. The effects of liraglutide on glucose, inflammatory markers, and lipoprotein metabolism: current knowledge and future perspective. Clin Lipidol. 2013;8(2):173\u201381.","journal-title":"Clin Lipidol"},{"issue":"3","key":"1817_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s13300-022-01217-z","volume":"13","author":"D Nikolic","year":"2022","unstructured":"Nikolic D, Patti AM, Giglio RV, Chianetta R, Castellino G, Mag\u00e1n-Fern\u00e1ndez A, et al. Liraglutide improved cardiometabolic parameters more in obese than in non-obese patients with type 2 diabetes: a real-world 18-month prospective study. Diabetes Ther. 2022;13(3):453\u201364. https:\/\/doi.org\/10.1007\/s13300-022-01217-z.","journal-title":"Diabetes Ther"},{"issue":"5","key":"1817_CR10","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3390\/biomedicines11051362","volume":"11","author":"AM Patti","year":"2023","unstructured":"Patti AM, Giglio RV, Allotta A, Bruno A, Di Bella T, Pantea Stoian A, et al. Effect of semaglutide on subclinical atherosclerosis and cardiometabolic compensation: a real-world study in patients with type 2 diabetes. Biomedicines. 2023;11(5):1362. https:\/\/doi.org\/10.3390\/biomedicines11051362.","journal-title":"Biomedicines"},{"issue":"11","key":"1817_CR11","doi-asserted-by":"publisher","first-page":"F889","DOI":"10.1152\/ajprenal.00267.2015","volume":"309","author":"MA Abdul-Ghani","year":"2015","unstructured":"Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol. 2015;309(11):F889-900. https:\/\/doi.org\/10.1152\/ajprenal.00267.2015.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"7","key":"1817_CR12","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.3390\/ijms23073651","volume":"23","author":"T Salvatore","year":"2022","unstructured":"Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, et al. An overview of the cardiorenal protective mechanisms of SGLT-2is. Int J Mol Sci. 2022;23(7):3651. https:\/\/doi.org\/10.3390\/ijms23073651.","journal-title":"Int J Mol Sci"},{"key":"1817_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100679","volume":"18","author":"FB Rivera","year":"2024","unstructured":"Rivera FB, Cruz LLA, Magalong JV, Ruyeras JMMJ, Aparece JP, Bantayan NRB, et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol. 2024;18:100679. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100679.","journal-title":"Am J Prev Cardiol"},{"issue":"1","key":"1817_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12933-025-02700-0","volume":"24","author":"O Schnell","year":"2025","unstructured":"Schnell O, Almandoz J, Anderson L, Barnard-Kelly K, Battelino T, Bl\u00fcher M, et al. CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes. Cardiovasc Diabetol. 2025;24(1):187. https:\/\/doi.org\/10.1186\/s12933-025-02700-0.","journal-title":"Cardiovasc Diabetol"},{"key":"1817_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaf037","author":"A Kalayci","year":"2025","unstructured":"Kalayci A, Januzzi JL, Mitsunami M, Tanboga IH, Karabay CY, Gibson CM. Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf037.","journal-title":"Eur Heart J"},{"issue":"2","key":"1817_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61020202","volume":"61","author":"IC Liang","year":"2025","unstructured":"Liang IC, Chang HH, Lai YJ, Chan CM, Sung CH, Pu CM, et al. Update on the efficacy and safety of sodium-glucose co-transporter 2 inhibitors in patients with chronic diseases: a systematic review and meta-analysis. Medicina (Kaunas). 2025;61(2):202. https:\/\/doi.org\/10.3390\/medicina61020202.","journal-title":"Medicina (Kaunas)"},{"key":"1817_CR17","doi-asserted-by":"publisher","unstructured":"Ghosal S, Ghosal A. Risk\u2013benefit trade-offs of GLP-1RAs and SGLT-2is in type 2 diabetes mellitus (T2D): systematic review, meta-analysis, and net benefit modelling. figshare. Journal contribution (2025). https:\/\/doi.org\/10.6084\/m9.figshare.30162679.v1.","DOI":"10.6084\/m9.figshare.30162679.v1"},{"issue":"4","key":"1817_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"23","key":"1817_CR19","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K\u00f8ber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1509225.","journal-title":"N Engl J Med"},{"issue":"13","key":"1817_CR20","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1612917.","journal-title":"N Engl J Med"},{"issue":"10157","key":"1817_CR21","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X.","journal-title":"Lancet"},{"issue":"10193","key":"1817_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"issue":"9","key":"1817_CR23","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1901118.","journal-title":"N Engl J Med"},{"issue":"19","key":"1817_CR24","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"10","key":"1817_CR25","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896\u2013907. https:\/\/doi.org\/10.1056\/NEJMoa2108269.","journal-title":"N Engl J Med"},{"issue":"2","key":"1817_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"20","key":"1817_CR27","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392(20):2001\u201312. https:\/\/doi.org\/10.1056\/NEJMoa2501006.","journal-title":"N Engl J Med"},{"issue":"22","key":"1817_CR28","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"4","key":"1817_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"issue":"7","key":"1817_CR30","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925.","journal-title":"N Engl J Med"},{"issue":"24","key":"1817_CR31","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"15","key":"1817_CR32","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2004967.","journal-title":"N Engl J Med"},{"issue":"2","key":"1817_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2030186.","journal-title":"N Engl J Med"},{"issue":"2","key":"1817_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa2030183.","journal-title":"N Engl J Med"},{"issue":"4","key":"1817_CR35","doi-asserted-by":"publisher","first-page":"250","DOI":"10.14740\/cr1523","volume":"14","author":"A Rahman","year":"2023","unstructured":"Rahman A, Alqaisi S, Saith SE, Alzakhari R, Levy R. The impact of glucagon-like peptide-1 receptor agonist on the cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis and systematic review. Cardiol Res. 2023;14(4):250\u201360. https:\/\/doi.org\/10.14740\/cr1523.","journal-title":"Cardiol Res"},{"issue":"23","key":"1817_CR36","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","volume":"149","author":"SM Patel","year":"2024","unstructured":"Patel SM, Kang YM, Im K, Neuen BL, Anker SD, Bhatt DL, et al. Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis. Circulation. 2024;149(23):1789\u2013801. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069568.","journal-title":"Circulation"},{"issue":"1","key":"1817_CR37","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12933-023-02035-8","volume":"22","author":"JY Chen","year":"2023","unstructured":"Chen JY, Pan HC, Shiao CC, Chuang MH, See CY, Yeh TH, et al. Impact of SGLT-2is on patient outcomes: a network meta-analysis. Cardiovasc Diabetol. 2023;22(1):290. https:\/\/doi.org\/10.1186\/s12933-023-02035-8.","journal-title":"Cardiovasc Diabetol"},{"issue":"2S","key":"1817_CR38","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.amjmed.2023.04.035","volume":"137","author":"JW Ostrominski","year":"2024","unstructured":"Ostrominski JW, Vaduganathan M. Chapter 2: Clinical and mechanistic potential of Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors in heart failure with preserved ejection fraction. Am J Med. 2024;137(2S):S9\u201324. https:\/\/doi.org\/10.1016\/j.amjmed.2023.04.035.","journal-title":"Am J Med"},{"issue":"1","key":"1817_CR39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/ceo.14445","volume":"53","author":"I Kapoor","year":"2025","unstructured":"Kapoor I, Sarvepalli SM, D\u2019Alessio DA, Hadziahmetovic M. Impact of glucagon-like peptide-1 receptor agonists on diabetic retinopathy: a meta-analysis of clinical studies emphasising retinal changes as a primary outcome. Clin Exp Ophthalmol. 2025;53(1):67\u201375. https:\/\/doi.org\/10.1111\/ceo.14445.","journal-title":"Clin Exp Ophthalmol"},{"issue":"6","key":"1817_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234065","volume":"15","author":"J Heyward","year":"2020","unstructured":"Heyward J, Mansour O, Olson L, Singh S, Alexander GC. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis. PLoS ONE. 2020;15(6):e0234065. https:\/\/doi.org\/10.1371\/journal.pone.0234065.","journal-title":"PLoS ONE"},{"issue":"1 Suppl 1","key":"1817_CR41","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025. Diabetes Care. 2025;48(1 Suppl 1):S181\u2013206. https:\/\/doi.org\/10.2337\/dc25-S009.","journal-title":"Diabetes Care"},{"issue":"1","key":"1817_CR42","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12933-025-02737-1","volume":"24","author":"N Chaiyakunapruk","year":"2025","unstructured":"Chaiyakunapruk N, Tan X, Liang Y, Guevarra M, Xie L, Cheng AYY. Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes. Cardiovasc Diabetol. 2025;24(1):177. https:\/\/doi.org\/10.1186\/s12933-025-02737-1.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1817_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2024.101594","volume":"51","author":"AJ Scheen","year":"2025","unstructured":"Scheen AJ. Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies. Diabetes Metab. 2025;51(1):101594. https:\/\/doi.org\/10.1016\/j.diabet.2024.101594.","journal-title":"Diabetes Metab"},{"key":"1817_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2025.171380","volume":"187","author":"CJ Bailey","year":"2025","unstructured":"Bailey CJ, Flatt PR, Conlon JM. Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides. 2025;187:171380. https:\/\/doi.org\/10.1016\/j.peptides.2025.171380.","journal-title":"Peptides"},{"issue":"3","key":"1817_CR45","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2217\/cer-2020-0137","volume":"10","author":"C Balijepalli","year":"2021","unstructured":"Balijepalli C, Yan K, Zoratti M, Franklin M, Druyts E. Heterogeneity in renal end points of cardiovascular outcomes trials in type 2 diabetes. J Comp Eff Res. 2021;10(3):169\u201373. https:\/\/doi.org\/10.2217\/cer-2020-0137.","journal-title":"J Comp Eff Res"},{"issue":"6","key":"1817_CR46","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/00325481.2024.2377529","volume":"136","author":"AK Singh","year":"2024","unstructured":"Singh AK, Farag YMK, Zheng Z, Bakris GL. Clinical trial designs of emerging therapies for diabetic kidney disease (DKD). Postgrad Med. 2024;136(6):585\u201393. https:\/\/doi.org\/10.1080\/00325481.2024.2377529.","journal-title":"Postgrad Med"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01817-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01817-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01817-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:17:47Z","timestamp":1769498267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01817-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1817"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01817-5","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Samit Ghosal and Anuradha Ghosal declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}